The trials are slated to begin in Q4 2021.

Aditx Therapeutics, Inc.’s AditxtReprogramming Therapeutics Division is preparing its to begin first-in-human clinical trials for psoriasis. 

The trials, which are slated to begin in Q4 2021, will evaluate clinical safety and efficacy of Aditxt's new approach to reprogramming and retraining the immune system using a nucleic acid-based technology named Apoptotic DNA Immunotherapy (ADi). 

ADi technology mimics the way the body naturally induces tolerance to its own tissues (therapeutically induced immune tolerance) and is protected with approximately 90 U.S. and international patents. ADi has demonstrated efficacy in several pre-clinical disease models including psoriasis in which a reduction in skin thickening and scaling, and modulation of key protein markers were observed. 

Aditxt has signed an agreement with a regulatory consultant based in Munich, Germany, which will play a central role in navigating the first AditxtReprogramming therapeutic program through the clinical trial and regulatory process.  The firm will work with the Aditxt's AditxtReprogramming team to submit an Investigational New Drug application (IND) to the regulatory agency in Germany.  

Psoriasis is the first indication being targeted for clinical trial in the AditxtReprogramming therapeutics pipeline. Other potential indications include ADi for Type 1 diabetes and skin allografting.